IP Library Patent Application 16154478
Patent Application
App. No. 16/154,478

METHOD OF TREATING PAIN

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/154,478
Abstract

The instant application discloses methods of treating, reducing, or preventing pain in a mammal, which may include administering a compound capable of modulating a transient receptor potential channel. In one aspect, the TRP channel may be TRPC4. Types of pain contemplated by the present disclosure include acute, chronic, neuropathic, and nociceptive pain.

Claims (48)

1 . A compound selected from

a)

wherein R is selected from

wherein R′ is selected from H, CH 3 , Et, or X, and

wherein R″ is selected from H or alkyl;

for use in a method for treating the human or animal body.

2 . The compound of claim 1 , wherein R is

wherein R′ is selected from H, CH 3 , Et, or X, and

wherein R″ is selected from H or alkyl.

3 . The compound of claim 1 or 2 , wherein R is

R′ is H, and R″ is CH 3 .

4 . The compound of any of claims 1 to 3 for use in treating, reducing, or preventing pain in a mammal.

5 . The compound of claim 4 , wherein the pain is selected from acute, chronic, neuropathic, nociceptive and visceral pain, and a combination thereof.

6 . The compound of claim 5 , wherein the pain comprises visceral pain.

7 . The compound of claim 5 , wherein the pain comprises neuropathic pain.

8 . The compound of any of claims 4 to 7 , wherein said compound is administered orally.

9 . The compound of any of claims 4 to 7 , wherein said compound is administered topically.

10 . A pharmaceutical composition comprising the compound of any of claims 1 to 7 and a pharmaceutical excipient.

11 . The pharmaceutical composition of claim 8 , further comprising one or more additional pharmaceutically active agents.

12 . The pharmaceutical composition of claim 9 , wherein said one or more additional pharmaceutically active agents are selected from non-opioid analgesics, opioid analgesics, anti-epileptics, NMDA antagonists, lidocaine, tricyclic antidepressants, or a combination thereof.

13 . A method of treating, reducing, or preventing pain in a mammal, comprising the step of administering a therapeutically effective amount of a composition to said mammal, wherein said composition comprises a compound selected from

a)

wherein R is selected from

wherein R′ is selected from H, CH 3 , Et, or X, and

wherein R″ is selected from H or alkyl;

b)

wherein R is selected from Aryl, heteroaryl, alkyl, cycloalkyl, H, and R′ is selected from H, aryl, heteroaryl, alkyl, cycloalkyl to a subject in need thereof, and wherein said compound is capable of modulating Trpc4 activity.

14 . The method of claim 13 , wherein said compound comprises

wherein R is

wherein R′ is selected from H, CH 3 , Et, or X, and

wherein R″ is selected from H or alkyl.

15 . The method of claim 13 or 14 , wherein said compound comprises

wherein R is

R′ is H, and R″ is CH 3 .

16 . The method of any of claims 13 to 15 , wherein said Trpc4 is human.

17 . The method of any of claims 13 to 16 , wherein said compound causes an increase in Trpc4 activity.

18 . The method of any of claims 13 to 16 , wherein said compound causes a decrease in Trpc4 activity.

19 . The method of any of claims 13 to 16 , wherein said compound functions as a Trpc4 antagonist.

20 . The method of claims 13 to 16 , wherein said compound functions as a Trpc4 agonist.

21 . The method of claim 14 , wherein said compound functions as a Trpc4 antagonist.

22 . The method of claim 14 , wherein said compound functions as a Trpc4 agonist.

23 . The method of any of claims 13 to 22 , wherein the pain is selected from the group consisting of acute, chronic, neuropathic, nociceptive, visceral, and a combination thereof.

24 . The method of claim 13 , wherein the pain comprises visceral pain.

25 . The method of claim 13 wherein the pain comprises neuropathic pain.

26 . The method of any of claims 13 to 25 , wherein said composition further comprises a second pharmaceutically active agent.

27 . The method of any of claims 13 to 26 , wherein said composition further comprises one or more additional pharmaceutically active agents selected from non-opioid analgesics, opioid analgesics, anti-epileptics, NMDA antagonists, lidocaine, tricyclic antidepressants, or a combination thereof.

28 . The method of any of claims 13 to 27 wherein said compound is administered orally.

29 . The method of any of claims 13 to 27 wherein said compound is administered topically.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2019
From: OSTERTAG, ERIC M.; CRAWFORD, JOHN STUART
To: TRANSPOSAGEN BIOPHARMACEUTICALS, INC.
Reel/Frame 048751/0045 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2019
From: TRANSPOSAGEN BIOPHARMACEUTICALS, INC.
To: POSEIDA THERAPEUTICS, INC.
Reel/Frame 048751/0104 →